| **Researcher Profile:** | **PD Dr. Caroline Bosch-Voskens, PhD** |
|---|---|
| **Born:** | 06.10.1977, female |
| **Address:** | FAU; University Hospital Erlangen<br>Department of Dermatology<br>Ulmenweg 18, D-91054 Erlangen |
| **Tel.:** | +49 9131 85 35000 |
| **E-Mail:** | caroline.bosch-voskens@uk-erlangen.de |
| **Current position & status:** | Attending physician, Department of Dermatology |
| **Delay of scientific career:** | 1 child (19.12.2014; employment ban 3 months; parental leave 7 months) |


## UNIVERSITYTRAINING AND DEGREE

**1998-2004** Medical School, University of Leiden, The Netherlands, MD degree

## ADVANCED ACADEMIC QUALIFICATIONS

**2020** Habilitation: "Immunotherapeutic strategies in cancer and autoimmune disease, FAU Erlangen, Germany. Mentor: Prof. Dr. med. Carola Berking

**2020** Additional board certification "Dermato-Oncology", Munich, Germany

**2017** Board certification Dermatology and Venerology, Munich, Germany

**2012** PhD: "Immunotherapeutic strategies in solid malignancies, Faculty of Medical Sciences, University of Groningen, The Netherlands
Supervisors: Prof. Dr. Hans Nijman, Prof. Scott Strome, Prof. Dean Mann

## POSTGRADUATE PROFESSIONAL CAREER

**2009-2017** Resident, Dept. of Dermatology, University Hospital Erlangen

**2005-2008** Research Fellow, University of Maryland, Baltimore, USA

## OTHER

**2021** Thiersch Preis (Habilitationspreis), Medizinische Fakultät, FAU Erlangen

**2021** Oscar-Gans-Förderpreis, German Society of Dermatology (DDG)

**2020 – 2021** Member of the Editorial Board, "Frontiers in Medicine", Research topic "Loss of Epithelial Barrier Integrity in Inflammatory diseases"

**Since 2018** Member of the Executive Board "Immune-Epithelial Communication in Inflammatory Bowel Disease" (CRC/TRR 241)

**2013** Selected to participate in the Academy for Future Leaders in Dermatology, European Society for Dermatological Research (ESDR), Florence, Italy

**2011** Best oral speaker, German Society of Dermatology (DDG)

## KEY PUBLICATIONS


**1** Mark C, Czerwinski T, Roessner S, Mainka A, Hörsch F, Heublein L, Winterl A, Sanokowski S, Richter S, Bauer N, Angelini TE, Schuler G, Fabry B, **Voskens CJ** (2020). Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells. ***Nat Commun*****.** 11(1):5224

**2** Wiesinger M, Stoica D, Roessner S, Lorenz C, Fischer A, Atreya R, Neufert CF, Atreya I, Scheffold A, Schuler-Thurner B, Neurath MF, Schuler G, **Voskens CJ** (2017). Good Manufacturing Practice-Compliant Production and Lot-Release of *Ex Vivo* Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders. ***Front Immunol*** 8:1371

**3** **Voskens CJ**, Fischer A, Roessner S, Lorenz C, Hirschmann S, Atreya R, Neufert C, Atreya I, Neurath MF, Schuler G (2017). Characterization and Expansion of Autologous GMP-ready Regulatory T Cells for TREG-based Cell Therapy in Patients with Ulcerative Colitis. ***Inflamm Bowel Dis*** 23(8):1348-1359

**4** **Voskens CJ**, Watanabe R, Rollins S, Campana D, Hasumi K, Mann DL. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity (2010). ***J Exp Clin Cancer Res*** 11;29:134.

**5** Lin W*, **Voskens CJ***, Zhang X, Schindler DG, Wood A, Burch E, Wei Y, Chen L, Tian G, Tamada K, Wang LX, Schulze DH, Mann D, Strome SE (2008). Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies. ***Blood*** 112(3):699-707. *shared first-authorship